Navigation Links
Boston Scientific Welcomes Publication of Gender Data Highlighting Benefits Women Receive From CRT-Ds
Date:2/8/2011

NATICK, Mass., Feb. 8, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today welcomed the publication of a sub-analysis of the MADIT-CRT trial data in the current issue of the Journal of American College of Cardiology that showed women received a greater clinical benefit from cardiac resynchronization therapy defibrillators (CRT-Ds) than men.

The sub-analysis demonstrated that both men and women experienced significant benefit from cardiac resynchronization therapy.  However, women experienced a 70 percent reduction in heart failure events compared to a 35 percent reduction for men.  Additional analysis demonstrated that women with asymptomatic or mild heart failure experienced a 72 percent reduction in all-cause mortality.

"CRT-D therapy has historically been underutilized in women compared to men with the same severity of heart disease," said Kenneth Stein, M.D., Senior Vice President and Chief Medical Officer, CRM, for Boston Scientific's Cardiology, Rhythm and Vascular Group.  "Boston Scientific believes that all patients, regardless of gender, should have equal access to high-quality cardiovascular care.  We believe these findings will help draw attention to the benefits of CRT-D treatment for women, and therefore help reduce treatment disparities between women and men."

A number of factors may have contributed to women experiencing a greater CRT-D benefit than men:

  • MADIT-CRT found that Left Bundle Branch Block (LBBB) is an objective discriminator for a positive response to CRT and women in the trial were more likely than men to have LBBB.  
  • CRT-D therapy is designed to improve the heart's overall pumping ability and women are more likely than men to have non-ischemic heart disease(1).  Conversely, men are more likely to have ischemic heart disease (also known as coronary artery disease), which often leads to a more localized impact on heart function.

  • MADIT-CRT is the world's largest randomized CRT-D study of New York Heart Association (NYHA) Class I and II patients(2), with more than 1,800 patients enrolled at 110 centers worldwide.  Results of the MADIT-CRT trial were published in the October 2009 issue of the New England Journal of Medicine.  

    About Boston ScientificBoston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

    Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding regulatory approvals, clinical trials and product performance.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

    Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.(1)  Non-ischemic heart disease typically affects the entire heart rather than a single region and can lead to reduced pumping strength, abnormal heart rhythms and disturbances in the heart's electrical system.(2)  The NYHA clinical classifications of heart failure rank patients as Class I-II-III-IV, according to the degree of symptoms or functional limits, from asymptomatic to bed ridden.  MADIT-CRT patients are asymptomatic or mildly symptomatic, NYHA Class I (ischemic) and Class II (ischemic and non-ischemic).CONTACT:

    Erik Kopp508-650-8660 (office)Media RelationsBoston Scientific CorporationSean Wirtjes508-652-5305 (office)Investor RelationsBoston Scientific Corporation
    '/>"/>

    SOURCE Boston Scientific Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. Boston Scientific Announces Results for Fourth Quarter and Full Year Ended December 31, 2010
    2. Boston Scientific Announces FDA Approval of Renegade® HI-FLO™ Fathom® Pre-Loaded System
    3. Boston Scientific Responds to DOJ Civil Lawsuit
    4. Boston Scientific Announces First Use of Blazer® Open-Irrigated Catheter in U.S.
    5. Boston Scientific Begins Clinical Trial Enrollment in China for PROMUS Element™ Everolimus-Eluting Stent
    6. Boston Scientific Completes Enrollment in EVOLVE Clinical Trial to Evaluate SYNERGY™ Drug-Eluting Coronary Stent
    7. Boston Scientific Announces Agreement With Fukuda Denshi for Distribution of Cardiac Rhythm Management Products in Japan
    8. Boston Scientific to Webcast Conference Call Discussing Fourth Quarter and Full Year 2010 Financial Results
    9. Boston Scientific to Acquire Atritech
    10. Boston Scientific Completes Enrollment in Clinical Trial Evaluating Next-Generation Nitinol Stent to Treat Iliac Artery Disease
    11. Statement of Kenneth Stein, M.D., Chief Medical Officer, Cardiac Rhythm Management, Boston Scientific on JAMA Article
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:2/10/2016)... ANGELES , Feb. 10, 2016  Oxis International ... cancer drug, OXS-1550, was described as a "clinical trial ... the drug went into complete cancer remission. ... University of Minnesota Masonic Cancer Center. --> ... University of Minnesota Masonic Cancer Center. --> ...
    (Date:2/10/2016)... , Feb. 10, 2016  LexisNexis® Risk Solutions, ... today announced the launch of LexisNexis Provider ... that helps improve and optimize the quality and ... performance using severity-adjusted scores. By measuring provider performance ... solution to deliver better outcomes, improve the patient ...
    (Date:2/10/2016)... Israel , February 10, 2016 /PRNewswire/ ... leader in the field of cartilage repair, announces the ... 5, 2016. The $15 million investment was led by ... pharmaceutical manufacturer, and was joined by existing Regentis investors ... and both the Technion Research & Development Foundation and ...
    Breaking Medicine Technology:
    (Date:2/10/2016)... ... February 10, 2016 , ... 10 Best Water ... were three leading bottled water brand owners that topped the list as a result ... and optimize conversion. The premier brand was Tibet 5100, a top notch water company ...
    (Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... advisory organization, welcomes S.S. Nesbitt as the latest addition to its growing list ... seven other locations throughout the Southeast, from Orlando to Huntsville and in between. ...
    (Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are ... patients. Research shows that the Goal Attainment Scale (GAS) captures 20% more change ... and learn more about the Goal Attainment Scale, Education Resources Inc. is offering ...
    (Date:2/10/2016)... ... 10, 2016 , ... IDEX Health & Science, LLC announces ... (PLS) columns combine the strength of traditional stainless steel with the chemical inertness ... while operating at ultra-high pressures of 20,000 psi. The higher operating pressures allow ...
    (Date:2/10/2016)... ... 10, 2016 , ... Anxiety of older Americans over steep cost increases of ... a decade ago, according to The Senior Citizens League (TSCL). Since ... coping with rapidly rising costs. “The implications are chilling, particularly for people with ...
    Breaking Medicine News(10 mins):